127 related articles for article (PubMed ID: 9308555)
1. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
Grossman D; Heald PW; Wang C; Rinder HM
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):409-13. PubMed ID: 9308555
[TBL] [Abstract][Full Text] [Related]
2. [Activated protein C resistance and cardiolipin antibodies in leg ulcers].
Maréchal V; De Maistre E; Barbaud A; Albuisson E; Lecompte T; Gobert B; Bene M; Faure G; Schmutz J
Ann Dermatol Venereol; 2000; 127(6-7):585-9. PubMed ID: 10930855
[TBL] [Abstract][Full Text] [Related]
3. Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers.
Gaber Y; Siemens HJ; Schmeller W
Br J Dermatol; 2001 Mar; 144(3):546-8. PubMed ID: 11260012
[TBL] [Abstract][Full Text] [Related]
4. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Deschiens MA; Conard J; Horellou MH; Ameri A; Preter M; Chedru F; Samama MM; Bousser MG
Stroke; 1996 Oct; 27(10):1724-30. PubMed ID: 8841318
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of factor V Leiden mutation in patients with leg ulcers and venous insufficiency.
Maessen-Visch MB; Hamulyak K; Tazelaar DJ; Crombag NH; Neumann HA
Arch Dermatol; 1999 Jan; 135(1):41-4. PubMed ID: 9923779
[TBL] [Abstract][Full Text] [Related]
6. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
[TBL] [Abstract][Full Text] [Related]
7. Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
Ciardella AP; Yannuzzi LA; Freund KB; DiMichele D; Nejat M; De Rosa JT; Daly JR; Sisco L
Retina; 1998; 18(4):308-15. PubMed ID: 9730172
[TBL] [Abstract][Full Text] [Related]
8. Factor V Leiden mutation in postthrombotic and non-postthrombotic venous ulcers.
Hafner J; Kühne A; Schär B; Bombeli T; Hauser M; Lüthi R; Hänseler E
Arch Dermatol; 2001 May; 137(5):599-603. PubMed ID: 11346337
[TBL] [Abstract][Full Text] [Related]
9. A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers.
Ribeaudeau F; Senet P; Cayuela JM; Fund X; Paul C; Robert C; Scrobohaci ML; Dubertret L
Br J Dermatol; 1999 Aug; 141(2):259-63. PubMed ID: 10468797
[TBL] [Abstract][Full Text] [Related]
10. [Increased prevalence of APC-resistance (factor V Leiden mutation) in patients with postthrombotic syndrome].
Gaber Y; Siemens HJ; Schmeller W
Hautarzt; 2000 Aug; 51(8):590-2. PubMed ID: 10997314
[TBL] [Abstract][Full Text] [Related]
11. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
[TBL] [Abstract][Full Text] [Related]
12. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation.
Bontempo FA; Hassett AC; Faruki H; Steed DL; Webster MW; Makaroun MS
J Vasc Surg; 1997 Feb; 25(2):271-5; discussion 276. PubMed ID: 9052561
[TBL] [Abstract][Full Text] [Related]
13. Activated protein C resistance in patients with peripheral vascular disease.
Sampram ES; Lindblad B; Dahlbäck B
J Vasc Surg; 1998 Oct; 28(4):624-9. PubMed ID: 9786256
[TBL] [Abstract][Full Text] [Related]
14. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
15. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
[TBL] [Abstract][Full Text] [Related]
16. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
17. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
18. Detection of factor V Leiden in Thai patients with venous thrombosis.
Prayoonwiwat W; Arnutti P; Hiyoshi M; Nathalang O; Suwanasophon C; Kokaseam R; Krutvecho T; Tatsumi N
Asian Pac J Allergy Immunol; 2000 Jun; 18(2):105-8. PubMed ID: 10928623
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden.
Zehnder JL; Benson RC
Am J Clin Pathol; 1996 Jul; 106(1):107-11. PubMed ID: 8701918
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Guasch JF; Lensen RP; Bertina RM
Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
